




# Artemether + lumefantrine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > For curative treatment

	<b>EMLc</b>	ATC codes: <b>P01BF01</b>
<b>Indication</b>	Malaria due to Plasmodium vivax	ICD11 code: <b>1F81</b>
<b>INN</b>	Artemether + lumefantrine	
<b>Medicine type</b>	Chemical agent	
<b>List type</b>	Core (EML) (EMLc)	
<b>Additional notes</b>	Not recommended in the first trimester of pregnancy or in children below 5 kg	
<b>Formulations</b>	Oral > Solid: 20 mg + 120 mg tablet ; 20 mg + 120 mg dispersible tablet (EMLc)	
<b>EML status history</b>	First added in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> )	
<b>Sex</b>	All	
<b>Age</b>	Also recommended for children	
<b>Weight restriction</b>	Children > 5 kg	
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine	
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 	
<b>Wikipedia</b>	<a href="#">Artemether + lumefantrine</a> 	
<b>DrugBank</b>	<a href="#">Artemether</a>  <a href="#">Lumefantrine</a> 	

## Summary of evidence and Expert Committee recommendations

Artemether + lumefantrine dispersible tablet formulation was added for children use in the treatment of malaria.

